Smith & Nephew - SNN STOCK NEWS

Smith+Nephew (NYSE:SNN) announced the successful completion of the first surgery using its JOURNEY II Medial Dished (MD) System for total knee arthroplasty (TKA). Performed by Dr. Ran Schwarzkopf at NYU Langone Health, this innovative system enhances knee kinematics and stability. The JOURNEY II MD aims to improve patient outcomes and satisfaction by replicating natural motion in knee replacements. The product is now available in the United States, following customer demand for medial dished inserts that expand clinical applications of the JOURNEY II Knee System.

Smith+Nephew (NYSE:SNN) expands its CORI Surgical System for total hip arthroplasty (THA), enhancing its advanced robotic capabilities. The RI.HIP NAVIGATION technology is now integrated, promising improved accuracy in component alignment. A recent study indicates that computer-guided THA can significantly reduce revision rates (1.06% vs. 3.88% for conventional methods). The system has received FDA clearance, with initial software installations set for select hospitals and Ambulatory Surgery Centers in the U.S., and broader availability anticipated in 2022.

Smith+Nephew (LSE:SN, NYSE:SNN) announced FDA clearance for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems. These systems are now indicated for closed surgical incisions to reduce the risk of superficial and deep surgical site infections (SSIs), post-operative seromas, and dehiscence. Over 500,000 patients in the U.S. experience SSIs annually, leading to 8,000 deaths. The PICO system has been used in about 2.3 million surgical cases over the last decade, proving effective in managing post-surgical complications.

Smith+Nephew (NYSE: SNN) has acquired Engage Surgical, the owner of the only cementless unicompartmental knee system available in the US, for up to $135 million based on sales. This acquisition supports Smith+Nephew's growth strategy, enhancing its product portfolio with unique offerings in the knee implant market. The Engage Surgical Partial Knee System aims to improve patient outcomes through biologic integration and lower surgery times. The US partial knee market is projected to grow at 4% annually, presenting significant opportunities for Smith+Nephew.

Smith+Nephew (NYSE:SNN) has launched the CORI™ handheld robotics, an advanced solution for total and partial knee arthroplasties. This compact and mobile system integrates a 3-D imaging system with a robotic sculpting tool, allowing for personalized surgeries tailored to patient anatomy. Surgeons report improved patient outcomes, including less pain and greater satisfaction, as it enables tailored operations. The system aims to streamline surgical processes and is part of Smith+Nephew's five-year innovation strategy to enhance surgical experiences through digital technology.

Smith+Nephew (NYSE: SNN) has announced the establishment of a new digital surgery and robotics innovation center in Munich, Germany. This center aims to unite healthcare professionals from Europe, the Middle East, and Africa with Smith+Nephew's R&D teams to advance digital surgery technologies, including the CORI™ robotic system. The facility will feature a dedicated medical education area for hands-on learning and is scheduled to open in late 2022. This development follows the company's recent robotics facility in Pittsburgh, enhancing its collaborative approach to medical education and product development.

Smith+Nephew has established its first dedicated Medical Education Centre in Singapore to enhance the training of healthcare professionals in the Asia Pacific region. Set to begin operations by mid-2022, the centre will focus on digital and robotic surgery, integrating Smith+Nephew's Real Intelligence ecosystem. It will offer advanced training technologies including augmented reality and hands-on digital operating rooms. This initiative aligns with the company's mission to improve patient outcomes and support healthcare professionals' continuous education.

Smith+Nephew (NYSE:SNN) has launched the LEGION CONCELOC Cementless Total Knee System, showcasing its first completed surgeries. Utilizing CONCELOC Advanced Porous Titanium, this 3D printed technology promotes biological bone ingrowth for better long-term fixation. The system aims to streamline surgical efficiency, addressing challenges faced with traditional cementless designs. Now available in North America, it will expand into Europe and Asia Pacific pending regulatory approvals. This innovation positions Smith+Nephew in a growing market segment.

Smith+Nephew (NYSE:SNN) released a systematic review showing that its IODOSORB 0.9% Cadexomer Iodine Range is over twice as effective in healing chronic wounds compared to standard care. The analysis included 13 studies focusing on conditions like venous leg ulcers, diabetic foot ulcers, and pressure ulcers. IODOSORB significantly reduces barriers to healing such as exudate and bacteria. The cost of chronic wounds is estimated at $3.9 billion in Canada, highlighting the importance of effective treatments like IODOSORB in improving patient outcomes and reducing healthcare costs.